{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:14:24Z","timestamp":1794244464966,"version":"4.9.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.transci.2023.103685","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T15:01:12Z","timestamp":1677423672000},"page":"103685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient\u2019s safety and survival outcome:A systematic narrative appraisal of where we are now!"],"prefix":"10.1016","volume":"62","author":[{"given":"Mohamed","family":"Shouman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Goubran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Burnouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1179\/1607845414Y.0000000161","article-title":"Anemia in malignancies: pathogenetic and diagnostic considerations","volume":"20","author":"Gaspar","year":"2015","journal-title":"Hematology"},{"issue":"Suppl 7A","key":"10.1016\/j.transci.2023.103685_bib2","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.transci.2023.103685_bib3","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2018.01294","article-title":"Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach","volume":"9","author":"Madeddu","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.transci.2023.103685_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102837","article-title":"Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia","volume":"145","author":"Abdel-Razeq","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.transci.2023.103685_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.005","article-title":"Acute and long-term adverse events associated with checkpoint blockade","volume":"35","author":"Davies","year":"2019","journal-title":"Semin Oncol Nurs"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib7","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2023.103685_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1054\/bjoc.2001.1750","article-title":"Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy","volume":"84 Suppl 1","author":"Demetri","year":"2001","journal-title":"Br J Cancer"},{"issue":"2 Suppl 8","key":"10.1016\/j.transci.2023.103685_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","article-title":"Symptomatology of anemia","volume":"28","author":"Ludwig","year":"2001","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7150\/jca.55159","article-title":"The association between pretreatment anemia and overall survival in advanced non-small cell lung cancer: a retrospective cohort study using propensity score matching","volume":"13","author":"Huang","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.transci.2023.103685_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CGM.S32797","article-title":"Impact of transfusion on cancer growth and outcome","volume":"9","author":"Goubran","year":"2016","journal-title":"Cancer Growth Metastas"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.transci.2017.05.014","article-title":"Red blood cell transfusion and outcome in cancer","volume":"56","author":"Iqbal","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib13","first-page":"253","article-title":"Effect of blood transfusions on subsequent kidney transplants","volume":"5","author":"Opelz","year":"1973","journal-title":"Transpl Proc"},{"key":"10.1016\/j.transci.2023.103685_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720748","article-title":"Efficacy of immune checkpoint inhibitors in rare tumours: a systematic review","volume":"12","author":"Petrelli","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.transci.2017.05.019","article-title":"Transfusion-related immunomodulation and cancer","volume":"56","author":"Goubran","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.transci.2017.05.023","article-title":"The microbiome and transfusion in cancer patients","volume":"56","author":"Goubran","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2023.103685_bib17","unstructured":"Goubran H., The microbiome and transfusion in cancer patients, International Society of blood transfusion, Plenary State of the Art, Educational Session, Barcelona, Spain, 2020. ISBT science series abstract PL-02\u201302: 4."},{"issue":"7","key":"10.1016\/j.transci.2023.103685_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.transci.2023.103685_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.hoc.2021.11.002","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"36","author":"Hwang","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"10.1016\/j.transci.2023.103685_bib24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/bloodadvances.2018019000","article-title":"Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab","volume":"2","author":"Hasanov","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.transci.2023.103685_bib25","doi-asserted-by":"crossref","first-page":"E362","DOI":"10.1002\/ajh.26273","article-title":"Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy","volume":"96","author":"Saliba","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy","volume":"9","author":"Palla","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000447508","article-title":"Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia","volume":"9","author":"Schwab","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"4","key":"10.1016\/j.transci.2023.103685_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hon.2338","article-title":"Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report","volume":"35","author":"Tardy","year":"2017","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.transci.2023.103685_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1752-1947-8-240","article-title":"Serious haematological toxicity during and after ipilimumab treatment: a case series","volume":"8","author":"Simeone","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.transci.2023.103685_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40425-017-0214-9","article-title":"Immunotherapy-associated autoimmune hemolytic anemia","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.transci.2023.103685_bib34","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network. management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.transci.2023.103685_bib36","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.transci.2023.103685_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.transci.2023.103685_bib38","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMc1509362","article-title":"Immunotherapy-associated hemolytic anemia with pure red-cell aplasia","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.transci.2023.103685_bib39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/CMR.0000000000000392","article-title":"A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma","volume":"27","author":"Yuki","year":"2017","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14740\/jh507","article-title":"Bone marrow findings of immune-mediated pure red cell aplasia following anti-programmed cell death receptor-1 therapy: a report of two cases and review of literature","volume":"8","author":"Le Aye","year":"2019","journal-title":"J Hematol"},{"issue":"16","key":"10.1016\/j.transci.2023.103685_bib41","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2169\/internalmedicine.4467-20","article-title":"Pembrolizumab-induced pure red cell aplasia successfully treated with intravenous immunoglobulin","volume":"59","author":"Isoda","year":"2020","journal-title":"Intern Med"},{"issue":"21","key":"10.1016\/j.transci.2023.103685_bib42","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103685_bib43","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"10","key":"10.1016\/j.transci.2023.103685_bib44","article-title":"Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature","volume":"12","author":"Ali","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib45","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J Oncol Pharm Pr"},{"key":"10.1016\/j.transci.2023.103685_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/10781552221088025","article-title":"Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab","author":"Gilbar","year":"2022","journal-title":"J Oncol Pharm Pr"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib47","first-page":"113","article-title":"Spectrum of immune checkpoint inhibitor anemias: results from a single center","volume":"11","author":"Nelson","year":"2022","journal-title":"Early-Phase Clin Trials Case Ser Exp J Hematol"},{"key":"10.1016\/j.transci.2023.103685_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.transci.2023.103685_bib49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.2019003810","article-title":"How I treat microangiopathic hemolytic anemia in patients with cancer","volume":"137","author":"Thomas","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13730-020-00454-0","article-title":"Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Lafranchi","year":"2020","journal-title":"CEN Case Rep"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot","year":"2021","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2023.103685_bib52","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103685_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdv580","article-title":"Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells","volume":"27","author":"Kanameishi","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.transci.2023.103685_bib55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000477968","article-title":"Immune thrombocytopenia induced by nivolumab in a metastatic non-small cell lung cancer patient","volume":"40","author":"Karakas","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.transci.2023.103685_bib57","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/DDDT.S167077","article-title":"Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies","volume":"12","author":"Sui","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.transci.2023.103685_bib60","article-title":"Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer","volume":"28","author":"Mori","year":"2019","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"4","key":"10.1016\/j.transci.2023.103685_bib62","first-page":"392","article-title":"Management of hematologic adverse events associated with immune checkpoint inhibitors","volume":"12","author":"Rogers","year":"2021","journal-title":"J Adv Pr Oncol"},{"key":"10.1016\/j.transci.2023.103685_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.765608","article-title":"Grade 4 neutropenia secondary to immune checkpoint inhibition - a descriptive observational retrospective multicenter analysis","volume":"11","author":"Zaremba","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.transci.2023.103685_bib64","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","article-title":"Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Petrelli","year":"2021","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib66","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.transci.2023.103685_bib67","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2958.2006.05311.x","article-title":"MAMPs and MIMPs: proposed classifications for inducers of innate immunity","volume":"61","author":"Mackey","year":"2006","journal-title":"Mol Microbiol"},{"issue":"2","key":"10.1016\/j.transci.2023.103685_bib68","first-page":"55","article-title":"The effect of probiotic use on ABO antibody titers","volume":"38","author":"Geraldo","year":"2022","journal-title":"Immunohematology"},{"issue":"5","key":"10.1016\/j.transci.2023.103685_bib69","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/trf.13477","article-title":"Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing","volume":"56","author":"Pa\u00efss\u00e9","year":"2016","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.transci.2023.103685_bib70","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001568","article-title":"Variations in oral microbiome and its predictive functions between tumorous and healthy individuals","volume":"71","author":"Yang","year":"2022","journal-title":"J Med Microbiol"},{"issue":"9","key":"10.1016\/j.transci.2023.103685_bib71","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.1994.12.9.1859","article-title":"Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery","volume":"12","author":"Heiss","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib72","article-title":"Perioperative blood transfusions for the recurrence of colorectal cancer","volume":"2006","author":"Amato","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.transci.2023.103685_bib73","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00595-020-02192-3","article-title":"Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis","volume":"51","author":"Petrelli","year":"2021","journal-title":"Surg Today"},{"issue":"1","key":"10.1016\/j.transci.2023.103685_bib74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12894-021-00926-0","article-title":"Blood transfusion had no influence on the 5-year biochemical recurrence after robot-assisted radical prostatectomy: a retrospective study","volume":"21","author":"Han","year":"2021","journal-title":"BMC Urol"},{"issue":"Suppl 3","key":"10.1016\/j.transci.2023.103685_bib75","first-page":"A180","article-title":"The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy","volume":"8","author":"D\u2019Avella","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.transci.2023.103685_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.976011","article-title":"Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors","volume":"13","author":"Mispelbaum","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2023.103685_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13099-020-00381-6","article-title":"Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review","volume":"12","author":"Miller","year":"2020","journal-title":"Gut Pathog"},{"issue":"6371","key":"10.1016\/j.transci.2023.103685_bib78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.transci.2023.103685_bib79","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.transci.2023.103685_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.iotech.2020.05.001","article-title":"Intervention strategies for microbial therapeutics in cancer immunotherapy","volume":"6","author":"Gopalakrishnan","year":"2020","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.transci.2023.103685_bib81","first-page":"15","article-title":"Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events","author":"Seghatchian","year":"2022","journal-title":"Transfus Apher Sci Dec"},{"key":"10.1016\/j.transci.2023.103685_bib82","doi-asserted-by":"crossref","unstructured":"Amiral J., Seghatchian J.: Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes Transfusion Apheresis Science December 2022[ in press].","DOI":"10.1016\/j.transci.2022.103625"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:54:24Z","timestamp":1761468864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1473050223000538"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103685","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient\u2019s safety and survival outcome:A systematic narrative appraisal of where we are now!","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103685"}}